Litigation Details for BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2016)

BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-22
Court	District Court, D. Delaware	Date Terminated	2018-02-07
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,579,019; 8,147,866
Link to Docket	External link to docket

Details for BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-22				External link to document
2016-12-21	38		United States Patent No. 7,579,019 ("the '019 patent") and United States Patent No. 8,147,…8,147,866 ("the '866 patent"), (collectively, "the Patents-in-Suit"), in connection…Court has subject matter jurisdiction over this patent infringement action (the "Action"). … Defendants acknowledge and agree that the Patents-in-Suit are valid, enforceable, and infringed…during the life of the '019 and '866 Patents, including any extensions and pediatric exclusivities	External link to document
2016-12-21	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,019 B2; 8,147,866 B2. (…2016 7 February 2018 1:16-cv-01303 830 Patent None District Court, D. Delaware	External link to document

BioDelivery Sciences International v. Teva Pharmaceuticals USA: BELBUCA Patent Litigation Summary

Last updated: August 5, 2026

BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:16-cv-01303-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Teva’s abbreviated new drug application for generic BELBUCA, a buprenorphine hydrochloride buccal film. BioDelivery asserted multiple patents covering the product, its mucoadhesive film technology, and methods of treating opioid dependence and chronic pain.

The case ended through a settlement rather than a trial judgment. Teva received a delayed generic-entry license, reportedly permitting commercial entry in January 2027, subject to contractual early-entry provisions. The settlement preserved BioDelivery’s market position for the principal commercial life of BELBUCA while avoiding a determination on patent validity or infringement.

What drug and patents were involved in the BioDelivery Sciences v. Teva case?

The litigation involved BELBUCA, a buprenorphine buccal film marketed for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. BELBUCA was approved by the FDA under NDA No. 207932 in October 2015.[1]

Teva filed an ANDA seeking approval to market a generic buprenorphine buccal film. BioDelivery alleged that Teva’s ANDA filing included Paragraph IV certifications challenging patents listed for BELBUCA in the FDA Orange Book.

Product and regulatory information

Item	Details
Brand	BELBUCA
Active ingredient	Buprenorphine hydrochloride
Dosage form	Buccal film
FDA pathway	NDA 207932
Reference sponsor	BioDelivery Sciences International
ANDA applicant	Teva Pharmaceuticals USA Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01303-RGA
Filing period	2016
Litigation type	Hatch-Waxman patent infringement
Outcome	Settlement and dismissal

The asserted patents were directed to BioDelivery’s film-based delivery platform and buprenorphine-containing compositions. Public case materials identify the following patent numbers as involved in the BELBUCA patent dispute:

Patent	General subject matter	Role in litigation
U.S. Patent No. 8,147,866	Buccal drug-delivery technology and bioadhesive compositions	Asserted patent
U.S. Patent No. 8,475,832	Drug-delivery compositions and film technology	Asserted patent
U.S. Patent No. 8,778,374	Buccal film and drug-delivery composition claims	Asserted patent
U.S. Patent No. 9,439,900	Buprenorphine film and related delivery claims	Asserted patent

The precise claim scope differed by patent. The overall estate sought to protect the combination of buprenorphine, a thin-film dosage form, mucoadhesion, drug release, and use of the product in the oral cavity.

When did BioDelivery sue Teva over generic BELBUCA?

BioDelivery filed the action in 2016 after receiving Teva’s Paragraph IV notice. The complaint triggered the Hatch-Waxman statutory stay, which generally prevents the FDA from approving the challenged ANDA for up to 30 months unless the litigation is resolved earlier or the court orders otherwise.[2]

BioDelivery’s complaint alleged that Teva’s proposed generic product would infringe the asserted BELBUCA patents. Teva’s Paragraph IV position would have placed patent validity, enforceability, and infringement at issue. The public record does not indicate that the court issued a final merits ruling invalidating or upholding the asserted patents.

Hatch-Waxman litigation timeline

Date or period	Event
October 2015	FDA approved BELBUCA NDA 207932
2016	Teva submitted an ANDA with Paragraph IV patent certifications
2016	BioDelivery filed Civil Action No. 1:16-cv-01303-RGA
2016-2017	Parties litigated infringement and validity issues
2017	Parties reached a settlement
2017-2018	Action was dismissed pursuant to the settlement
January 2027	Reported contractual date for Teva generic entry, subject to settlement terms

What was the outcome of the BioDelivery v. Teva litigation?

The case was resolved by settlement. The parties did not proceed to a final trial decision on patent infringement, obviousness, anticipation, written description, enablement, or enforceability.

The settlement reportedly allowed Teva to launch a generic version of BELBUCA on January 1, 2027. The agreement also reportedly included provisions that could permit earlier entry under defined circumstances. The complete settlement terms were not publicly disclosed.

The practical result was a delayed-entry license. BioDelivery avoided the risk of an adverse patent judgment and Teva obtained a defined future launch date. Because the agreement did not produce a published merits opinion, the case provides limited precedent for evaluating the validity of the BELBUCA patent estate.

Was the case dismissed with prejudice?

The litigation was dismissed after settlement. The dismissal reflected resolution of the dispute between the parties and did not constitute a judicial finding that the asserted patents were valid, enforceable, or infringed.

A settlement dismissal also does not establish that Teva’s proposed product would have infringed the asserted claims. The commercial terms, rather than a court judgment, controlled the timing of generic competition.

What Paragraph IV challenges did Teva make?

Teva’s ANDA certification challenged the patents listed for BELBUCA. In a typical Paragraph IV case, the ANDA applicant asserts that the relevant patents are invalid, unenforceable, or would not be infringed by the proposed generic product.[2]

The public docket and litigation reporting identify the dispute as involving BioDelivery’s BELBUCA patents, but the settlement prevented a final adjudication of Teva’s specific invalidity and noninfringement theories. The record therefore does not establish which claim limitations would have controlled the outcome at trial.

The central technical issues likely included:

• Whether Teva’s film contained the same or equivalent drug-delivery components.
• Whether the proposed product satisfied the asserted mucoadhesion and release limitations.
• Whether the claimed compositions were obvious in view of prior buccal and transmucosal delivery systems.
• Whether the asserted claims had adequate written-description and enablement support.
• Whether BioDelivery could enforce the patents against Teva’s ANDA product.

What is the Orange Book status of BELBUCA?

BELBUCA is an FDA-approved small-molecule drug, not a biologic. Its patent protections are evaluated through the FDA Orange Book and Hatch-Waxman framework rather than the biosimilar pathway under the Public Health Service Act.

The relevant Orange Book protections have included patents directed to BELBUCA’s formulation, dosage form, and method of use. Orange Book listing status can change as patents issue, expire, are delisted, or are challenged.

Orange Book and exclusivity considerations

Protection	Relevance to BELBUCA
New chemical entity exclusivity	Not the principal barrier in the Teva case because BELBUCA contains buprenorphine, an established active ingredient
New drug approval	FDA approval under NDA 207932
Formulation patents	Core protection for the buccal film and delivery system
Method-of-use patents	May cover treatment of pain or related clinical use limitations
Paragraph IV litigation	Used to challenge listed patents before generic approval
30-month stay	Delayed FDA approval during the statutory litigation period
Settlement license	Established a negotiated generic-entry date

The key commercial protection did not come from a new chemical entity exclusivity period. It came from patent protection for the buccal film formulation and the negotiated settlement restriction on Teva’s launch.

What formulation patents protect BELBUCA?

BELBUCA’s patent strategy centers on the delivery system rather than on buprenorphine as a chemical entity. The product uses a thin, dissolvable buccal film designed to adhere to the inside of the cheek and deliver buprenorphine across the oral mucosa.

Formulation claims can protect:

• The composition of the film-forming matrix.
• The presence and concentration of buprenorphine.
• Mucoadhesive polymers.
• Film thickness and physical properties.
• Drug-release characteristics.
• Layered or homogeneous film structures.
• The location and duration of buccal administration.
• Dose delivery through the oral mucosa.

This structure creates a higher technical barrier than a conventional immediate-release tablet. A generic applicant must design around the claims or accept the risk that its product will meet the limitations literally or under the doctrine of equivalents.

The settlement prevented the court from determining whether Teva’s proposed film would have fallen within the asserted claim scope.

What method-of-use patents protect BELBUCA?

BELBUCA’s commercial indications include pain management in patients requiring an opioid analgesic. Method-of-use claims may limit administration of buprenorphine through the buccal film for specified pain conditions, patient populations, dose ranges, or treatment protocols.

Method-of-use patents can remain commercially relevant after composition patents are challenged, but their value depends on the ANDA labeling and the ability to establish induced infringement. A generic applicant may attempt to avoid infringement through a section viii statement that removes a patented indication from its labeling, where FDA rules permit that approach.

The Teva settlement avoided a ruling on whether the proposed labeling or product use would have infringed any asserted method-of-use claims.

Did BioDelivery have a strong patent estate for BELBUCA?

BioDelivery had a meaningful but finite patent estate. Its strengths were concentrated in the product’s specialized buccal film and drug-delivery technology.

Strengths

1. The patents covered more than the active ingredient. They targeted formulation and delivery features that were central to the product’s commercial identity.
2. BELBUCA required a specialized dosage form rather than a conventional oral solid.
3. Multiple issued patents created overlapping claim categories.
4. The settlement secured a delayed generic launch rather than exposing the entire estate to a validity judgment.

Limitations

1. Buprenorphine was an established active ingredient, so chemical-entity exclusivity was limited.
2. Film-based transmucosal delivery had substantial prior-art exposure.
3. Formulation patents can face obviousness challenges based on combinations of known polymers, films, and drug-delivery techniques.
4. The absence of a merits decision leaves the enforceability and validity of the estate unresolved.
5. The economic value of the patents depended heavily on the timing of generic entry and the commercial erosion rate after launch.

The settlement outcome supports a conclusion that BioDelivery obtained commercially useful protection, but it does not prove that every asserted claim would have survived trial.

What generic-entry risks exist for BELBUCA?

The primary generic-entry risk was contractually delayed rather than immediate. Teva’s reported January 2027 launch date limits the period during which BioDelivery could expect a fully protected BELBUCA market from this specific challenger.

Potential post-entry risks include:

• Price erosion from Teva’s generic buprenorphine film.
• Pharmacy and payer substitution.
• Loss of formulary preference.
• Additional ANDA filings by other manufacturers.
• Paragraph IV challenges to later-issued or listed patents.
• Authorized-generic competition.
• Labeling disputes involving pain indications.
• Manufacturing or supply advantages held by generic competitors.

A settlement with one ANDA applicant does not prevent other applicants from filing separate ANDAs. It also does not guarantee that later applicants will accept the same launch date.

Which companies challenge BELBUCA’s market position?

Teva was the principal litigant in the identified case. The broader competitive set includes manufacturers capable of developing buprenorphine oral films, buccal systems, sublingual products, or other transmucosal dosage forms.

BELBUCA also competes clinically with other buprenorphine products and opioid analgesics, although those products may not be therapeutically or legally substitutable. Suboxone and generic buprenorphine-naloxone products are primarily associated with opioid-use-disorder treatment and are not direct generic substitutes for BELBUCA’s FDA-approved pain indication.

No biosimilar risk applies because BELBUCA is a small-molecule drug. The relevant threat is generic ANDA competition.

What licensing and commercial transactions affect BELBUCA?

BioDelivery’s commercial rights and corporate ownership have changed since the Teva case. BioDelivery developed BELBUCA and commercialized the product before later corporate transactions involving its assets and business.

The litigation analysis should distinguish between:

• The patent owner at the time of the 2016 complaint.
• The NDA holder and commercial seller at the time of the settlement.
• Any later licensee, acquirer, or successor holding BELBUCA rights.
• The party entitled to enforce the asserted patents.
• The party receiving settlement consideration or launch-related rights.

Those changes affect revenue allocation and enforcement authority but do not alter the historical outcome of Civil Action No. 1:16-cv-01303-RGA.

How does the Teva case affect BELBUCA revenue exposure?

The settlement protected revenue from Teva competition until the negotiated launch date, subject to the agreement’s early-entry provisions. The value of that protection depended on BELBUCA sales, payer coverage, net pricing, competing opioid therapies, and the number of generic entrants at launch.

The principal revenue scenarios were:

Scenario	Commercial effect
No early entry	Continued branded protection until the agreed January 2027 date
Teva entry in January 2027	Initial generic price and volume pressure
Multiple generic entrants	Faster price erosion and greater substitution
Earlier contractual entry	Reduced remaining branded revenue
Successful later patent enforcement	Potentially extended protection against additional entrants
Weak post-launch generic uptake	Slower erosion but limited strategic certainty

The settlement reduced litigation volatility but did not eliminate market risk after the agreed launch date.

What is the current litigation status?

The BioDelivery v. Teva action is closed following settlement and dismissal. There is no reported final trial verdict in the case and no reported Federal Circuit merits decision establishing the validity or infringement of the asserted BELBUCA patents.

The case remains relevant for commercial diligence because it established a negotiated generic-entry framework for Teva and illustrates the limits of relying on patent listings alone. The decisive business information is the settlement’s launch date and any provisions allowing earlier entry.

Key Takeaways

• The case involved Teva’s Paragraph IV ANDA for generic BELBUCA buccal film.
• BioDelivery asserted U.S. Patent Nos. 8,147,866, 8,475,832, 8,778,374, and 9,439,900.
• BELBUCA was approved under FDA NDA 207932 in October 2015.
• The litigation ended by settlement, not by a patent-validity or infringement judgment.
• Teva reportedly received a license to launch on January 1, 2027, subject to potential early-entry provisions.
• BELBUCA’s protection rests primarily on formulation, buccal-film, delivery-system, and method-of-use patents.
• Biosimilar competition is not relevant because buprenorphine is a small-molecule active ingredient.
• The settlement protects against the specific Teva challenge but does not bar other generic applicants.
• The case provides limited precedent on the strength of the asserted patents because no merits opinion was issued.

FAQs About BioDelivery Sciences International v. Teva

What was the drug at issue in 1:16-cv-01303?

The drug was BELBUCA, a buprenorphine hydrochloride buccal film approved for severe chronic pain requiring opioid treatment.

Did Teva win the BioDelivery BELBUCA patent case?

Neither party obtained a merits victory. The case ended in a settlement and dismissal, with Teva receiving a negotiated future launch right.

When can Teva launch generic BELBUCA?

The reported settlement date is January 1, 2027, subject to provisions that may allow earlier entry under specified circumstances.

Does the case create patent precedent for buprenorphine films?

No significant merits precedent resulted because the court did not issue a final published decision resolving patent validity or infringement.

Are biosimilars a competitive threat to BELBUCA?

No. BELBUCA contains the small-molecule drug buprenorphine. Competition proceeds through the ANDA generic-drug pathway, not through biosimilar approval.

References

1. U.S. Food and Drug Administration. (2015). BELBUCA (buprenorphine hydrochloride) buccal film, NDA 207932: Approval letter and prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications.
3. U.S. District Court for the District of Delaware. (2016). BioDelivery Sciences International, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:16-cv-01303-RGA.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center records for U.S. Patent Nos. 8,147,866; 8,475,832; 8,778,374; and 9,439,900.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.